Does cellular iron dysregulation play a causative role in Parkinson's disease?

Ageing Research Reviews
Deepinder Kaur, Julie Andersen

Abstract

Selective dopaminergic cell loss in Parkinson's disease is correlated with increased levels of cellular iron. It is still hotly debated as to whether the increase in iron is an upstream event which acts to promote neurodegeneration via formation of oxidative stress or whether iron accumulates as a by-product of the neuronal cell loss. Here we review evidence for loss of iron homeostasis as a causative factor in disease-associated neurodegeneration and the primary players which may be involved. A series of recent studies suggest that iron regulatory proteins (IRPs) coordinate both cellular iron levels and energy metabolism, both of which are disrupted in Parkinson's disease (PD) and may in turn contribute to increased levels of oxidative stress associated with the disease. Iron has also been recently been implicated in promotion of alpha-synuclein aggregation either directly or via increasing levels of oxidative stress suggesting an important role for it in Lewy body formation, another important hallmark of the disease.

References

Dec 1, 1992·Journal of the Neurological Sciences·S HallT Schallert
Mar 1, 1991·Journal of Neurochemistry·E SoficM B Youdim
Jan 1, 1990·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·K JellingerM B Youdim
Feb 1, 1989·Journal of Neurochemistry·P RiedererM B Youdim
Jan 1, 1968·Journal of Neuropathology and Experimental Neurology·K M Earle
Aug 1, 1995·Journal of Neurochemistry·D A LoefflerP A LeWitt
Jan 1, 1994·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·W WesemannP Riederer
Jun 23, 1995·The Journal of Biological Chemistry·E L KwakF M Torti
Jan 10, 1995·Archives of Biochemistry and Biophysics·E A MartinsR Meneghini
Dec 1, 1994·Annals of Neurology·V M MannA H Schapira
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·M B YoudimP Riederer
Apr 1, 1993·Neurology·A AntoniniM Anliker
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·A YoritakaY Mizuno
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·M W Hentze, L C Kühn
May 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·F Q YeW R Martin
May 1, 1996·Journal of Neurochemistry·Y GlinkaM B Youdim
May 26, 1998·Journal of Neuropathology and Experimental Neurology·P A CastelnauH C Powell
Oct 8, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Oct 15, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Aug 6, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·E GrünblattM B Youdim
Dec 23, 1999·Human Molecular Genetics·J L BradleyA H Schapira
May 29, 2000·Current Opinion in Genetics & Development·H R de SilvaN W Wood
Jul 6, 2000·Journal of Neuroscience Research·J E DudaJ Q Trojanowski
Aug 10, 2000·The American Journal of Pathology·L J HsuE Masliah
Aug 15, 2000·Annual Review of Nutrition·R S Eisenstein

❮ Previous
Next ❯

Citations

Feb 4, 2010·Environmental Monitoring and Assessment·Luis F O SilvaFrans Waanders
Apr 2, 2008·Antioxidants & Redox Signaling·Cecilia Hidalgo, Paulina Donoso
Mar 11, 2008·Antioxidants & Redox Signaling·Elizabeth L MacKenzieYoshiaki Tsuji
Apr 5, 2011·Antioxidants & Redox Signaling·Yuxing ZhangJi Zhang
Oct 1, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jorn-Hon LiuHsiao-Ming Chao
Sep 15, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jason R Cannon, J Timothy Greenamyre
May 20, 2006·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Kiyomitsu OyanagiMasayuki Yasui
Sep 24, 2011·Advances in Pharmacological Sciences·Varsha ShuklaHarish C Pant
Jul 4, 2012·International Journal of Cell Biology·Ross B Mounsey, Peter Teismann
Feb 23, 2011·International Journal of Molecular Sciences·Elizabeth A MazzioKaram F A Soliman
Jan 15, 2011·International Journal of Alzheimer's Disease·Gabriela A SalvadorNorma M Giusto
Feb 3, 2007·Proceedings of the National Academy of Sciences of the United States of America·Michelle SmeyneRichard Jay Smeyne
Nov 23, 2006·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Joanna ChwiejMarek Lankosz
May 4, 2010·Mechanisms of Ageing and Development·Jinze XuChristiaan Leeuwenburgh
Nov 26, 2008·Journal of Neuroscience Methods·Shalom MichaeliWalter C Low
Oct 22, 2008·Biochimica Et Biophysica Acta·John Beard, Okhee Han
Mar 25, 2008·Biochimica Et Biophysica Acta·Shankar J Chinta, Julie K Andersen
Sep 18, 2007·Progress in Neurobiology·Ya Ke, Zhong Ming Qian
Nov 4, 2004·NMR in Biomedicine·John F Schenck, Earl A Zimmerman
Jan 28, 2009·Human Brain Mapping·Patrice PéranUmberto Sabatini
Dec 7, 2007·Journal of Magnetic Resonance Imaging : JMRI·Patrice PéranUmberto Sabatini
Dec 7, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Shalom MichaeliPaul Tuite
Feb 3, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Giancarlo LogroscinoAlberto Ascherio
Apr 20, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Tua AnnanmakiKari Murros
Apr 4, 2016·Molecular Neurobiology·Hong JiangJunxia Xie
Apr 20, 2010·Chemico-biological Interactions·Susana Rivera-MancíaSergio Montes
Dec 25, 2012·Free Radical Biology & Medicine·Faten ShaeibHusam M Abu-Soud
Jul 7, 2015·Oxidative Medicine and Cellular Longevity·Jia-Jia XiaoXiao-Ping Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.

Related Papers

Annals of the New York Academy of Sciences
Mario E GötzP Riederer
Nature Reviews. Neuroscience
L ZeccaRobert R Crichton
Biochemical Pharmacology
Srinivas BharathJulie Andersen
© 2022 Meta ULC. All rights reserved